White Paper · Free PDF

Securing GLP-1 & Peptide Manufacturing Capacity: A Sourcing and Risk Framework for Sponsors and Investors

5-page PDFSourcing frameworkFree · emailed to you

Demand for GLP-1 and other therapeutic peptides has outpaced qualified manufacturing capacity, and sponsors are now competing for a limited pool of CDMO slots. This white paper gives you a structured way to assess capacity options, weigh building versus reserving supply, and stress-test the risks before a shortfall stalls a launch.

Inside this white paper

● A framework for mapping peptide/GLP-1 demand against qualified CDMO capacity
● How to weigh reserving capacity, building in-house, or partnering — and when each fits
● A supply-risk checklist covering raw materials, fill-finish and second sourcing
● A capacity-sourcing template to take into CDMO negotiations

Written for: Manufacturing Strategy, Supply Chain & Business Development teams in pharma and biotech — and investors assessing supply risk.

Why we share this free

These frameworks are how we start conversations with teams facing real decisions. Read it, use it in your own analysis — there's no obligation and no hard sell.

Get the free white paperEmailed to your inbox in minutes

Where should we send it?

One short step. We'll email the PDF straight to your inbox.

Request received

Thanks — we've received your request. A member of our team will email you the white paper shortly.

📩 When it arrives, please also check your Spam / Junk / External folder and mark us as safe so you don't miss it.

Prefer to talk now? Schedule an analyst call →